A Historical Review of the Accounting Treatment of Research and Development Costs

Company A has obtained a loan from Company B, another pharmaceutical company, to finance the late-stage development of a drug to treat cancer. Company A should expense the donation (generally as selling, general and administrative expense) when incurred (normally when paid) or at the time an unconditional promise to give cash is made, whichever is sooner. Under the contractual terms of the agreement, the milestone payment becomes payable upon the resolution of a contingency. Company A should accrue the milestone payment when the achievement of the milestone is probable (the amount of the payment is reasonably estimable, as it is a fixed amount under the terms of the arrangement).

Create a free account to unlock this Template

Original investigation directed primarily towards the advancement of knowledge,” while applied research was defined as “. Original investigation directed primarily towards solving recognized practical problems.” This distinction was made to assist the practitioner in evaluating the classification of specific costs. From these definitions, it appears distinguishing between devel-opment costs and applied research costs is an enigmatic chore.

INTANGIBLE ASSETS

• Research is original and planned investigation, undertaken with the prospect of gaining new scientific or technical knowledge and understanding.
• Accounting standards require companies to expense all research and development expenditures as incurred.
• If a company acquires another whose main business is to conduct R&D, costs are generally reported in the same way as they were by the acquired company.
• However, it does not provide the possible applications of concepts or phenomena in production.
• The two exceptions to this rule are (1) R&D under contract for others, and (2) plant and equipment (an R&D lab) which has alternative future uses.

Thus, in comparison to other costs that are capitalized, R&D costs do not seem to be of any greater uncertainty or risk. During the research phase, costs are expensed as incurred, reflecting the uncertainty and exploratory nature of these activities. However, once a project moves into the development phase, costs can be capitalized if certain conditions are met. These conditions include demonstrating technical feasibility, the intention to complete the asset, the ability to use or sell the asset, and the availability of adequate resources to complete the development. This approach ensures that only expenditures likely to generate future economic benefits are capitalized, providing a more accurate representation of a company’s financial position.

• Capitalizing R&D costs increases the equity base, potentially lowering the debt-to-equity ratio and presenting a stronger balance sheet.
• Under IFRS rules, research spending is treated as an expense each year, just as with GAAP.
• Since exercisability of the buy-back option is only triggered upon regulatory approval, the payment made by Company A to reacquire the rights would be capitalized when the option is exercised and then amortized over the useful life of the right.
• Combined with these new opportunities are a set of constraints that will require R&D to do more with less.
• At the same time, advances in digital and analytics techniques applied to an expanding array of data open new pathways to innovation in both medical advances and how R&D work gets done.

Find Products & Services

• However, significant improvements to quality, design or effectiveness that increase a company’s profits will be treated as ongoing maintenance expenses.
• These conditions include demonstrating technical feasibility, the intention to complete the asset, the ability to use or sell the asset, and the availability of adequate resources to complete the development.
• Company A has not yet concluded if economic benefits are likely to flow from the compound or if relevant regulatory approval will be granted.
• When it became apparent to the auditor and to others that these costs had no future benefit, they were written off.
• Detailed documentation is essential to substantiate these claims, as the IRS requires rigorous proof of eligibility.

Although the payment is non-refundable, Company A will receive a future benefit (the rights to the research) as the CRO performs the research services over the two-year period. Company A should continue to evaluate whether it expects the goods to be delivered or services to be rendered each reporting period to assess recoverability. Another fundamental principle is the consistent application of accounting policies. Companies must establish clear guidelines for recognizing and measuring R&D costs, ensuring that these policies are applied uniformly across all projects. This consistency not only aids in internal financial management but also enhances the comparability of financial statements over time, providing stakeholders with a reliable basis for evaluating the company’s performance. If the R&D backbone is overlooked, creating lasting change at scale will be difficult.

• Accounting for research and development (R&D) expenses requires careful consideration due to their impact on cash flow statements (accrual vs. cash basis accounting) as well as taxation rules (capitalizing vs. expensing).
• Company A entered into a collaboration arrangement with Company B. Company A paid Company B an upfront fee upon signing the arrangement and will pay Company B a discrete milestone payment of $2 million upon FDA approval.
• For example, costs in relation to the general partner are typically recorded as services delivered during the period of the project, while limited partners record their investment as R&D expenses.
• Today, the pressure is even greater to change the trajectory of R&D speed and success.
• Another study esti-mated exceedingly high new product failure rates, ranging from 30 to 90 percent.
• For example, one study of a number of industries found that an average of less than 2 percent of new product development projects were commercially successful” [Higgins, 1954].

To the extent that they are ordinary and necessary they are deduct-ible; to the extent that they are capital in nature they are to be capitalized and amortized over useful life. Losses are permitted where amounts have been capitalized in connection with abandoned projects, and recovery through amortization is provided where useful life of these capital items is determinable, as in the case of a patent. However, where projects are not abandoned and where a useful life cannot definitely be determined, taxpayers have had no means of amortizing research expenditures. Businessmen, constantly on the alert for immediate benefits, increased political pressure on Congress to allow the immediate deduction of R&D costs for tax purposes.

For new or inexperienced team members, it takes time to learn how an organization works and build critical business, technical, and leadership capabilities, especially in a remote or hybrid working environment. And as new specialty areas emerge and digital and analytical skills come to the fore, the demands on R&D expertise are only intensifying. When R&D organizations put their backbone in place and move toward their future state, they are not engaged in a one-off exercise. To maintain a leadership position, they need to keep incorporating new ways of working into their operating model as new opportunities emerge and the portfolio shifts.

R&D Capitalization vs Expense

If no future benefits are generated, it would certainly be irrational for a firm to undertake an R&D project. However, many studies show the marginal rate of return on R&D is either comparable to or greater than investment return on the capital r&d accounting expenditures. Denison [1962] calculated the rate of return on R&D to be about the same as for plant and equipment expendi-tures, but he assumed no time lag. The return rate for R&D investment would have been much greater with a time lag.

R&D Accounting

©  2024 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. In-depth analysis, examples and insights to give you an advantage in understanding the requirements and implications of financial reporting issues. KPMG has market-leading alliances with many of the world’s leading software and services vendors. Leveraging technology such as artificial intelligence (AI) or machine learning (ML) algorithms can help automate tedious tasks like document review or image recognition which would otherwise require significant manual effort.

What Are Research and Development (R&D) Expenses?

These include office supplies needed by researchers working on the project or software licenses required for running simulations. Tracking R&D costs is important because it allows companies to measure the effectiveness of their investment in innovation. It also helps them identify areas where they may be able to save money or increase efficiency.

The part that is spent on research is recorded as an expense but the development cost is recorded as an asset. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation.